• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Absci Corporation

    3/24/26 4:52:15 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email
    S-8 1 s-8x2026x03x2026evergreeni.htm S-8 Document

    As filed with the Securities and Exchange Commission on March [24], 2026
    Registration No. 333-            
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM S-8
    REGISTRATION STATEMENT
    Under The Securities Act of 1933
     
     
    ABSCI CORPORATION
    (Exact name of registrant as specified in its charter)
     
    Delaware 85-3383487
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S. Employer
    Identification No.)
    18105 SE Mill Plain Blvd
    Vancouver, WA
     98683
    (Address of Principal Executive Offices)         

     
    (Zip Code)
    Absci Corporation 2021 Stock Option and Incentive Plan
    Absci Corporation 2021 Employee Stock Purchase Plan
    (Full title of the plans)
    Sean McClain
    Founder and Chief Executive Officer
    18105 SE Mill Plain Blvd
    Vancouver, WA 98683
    (Name and address of agent for service)
    (360) 949-1041
    (Telephone number, including area code, of agent for service)
     
    Copies to:



    Maggie Wong
    Alicia Tschirhart
    Goodwin Procter LLP
    525 Market Street
    San Francisco, CA 94105
    (415) 733-6000
     
    Zachariah Jonasson
    Chief Financial Officer and Chief Business Officer
    Absci Corporation
    18105 SE Mill Plain Blvd
    Vancouver, WA 98683
    (360) 949-1041
     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
    Large accelerated filer
    ☐
    Accelerated filer
    ☐
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒
    Emerging growth company
    ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 registers (i) 7,575,754 additional shares of the Registrant’s common stock, $0.0001 par value per share (the “Common Stock”) under the Absci Corporation 2021 Stock Option and Incentive Plan (the “2021 Plan”) and (ii) 1,515,151 additional shares of Common Stock under the Absci Corporation 2021 Employee Stock Purchase Plan (the “2021 ESPP”).

    The number of shares of Common Stock reserved and available for issuance under the 2021 Plan is subject to an automatic annual increase on each January 1, beginning January 1, 2022, by an amount equal to the lesser of: (i) 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, and (ii) such lesser number of shares of Common Stock as determined by the Administrator (as defined in the 2021 Plan). The number of shares of Common Stock reserved and available for issuance under the 2021 ESPP is subject to an automatic annual increase on each January 1, beginning January 1, 2022 and each January 1 thereafter through January 1, 2031, by an amount equal to the lesser of: (i) 1,807,500 shares of Common Stock, (ii) 1% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, and (iii) such number of shares of Common Stock as determined by the Administrator (as defined in the 2021 ESPP). Accordingly, on January 1, 2026, the number of shares of Common Stock reserved and available for issuance under the (i) 2021 Plan increased by 7,575,754 and (ii) 2021 ESPP increased by 1,515,151 The additional shares are of the same class as other securities relating to the 2021 Plan and 2021 ESPP for which the Registrant’s registration statements filed on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on July 28, 2021 (File No. 333-258209), on March 22, 2022 (File No. 333-263772), on March 30, 2023 (File No. 333-270995), on March 21, 2024 (File No. 333-278140) and on March 18, 2025 (File No. 333-285883) are effective, which registration statements are hereby incorporated by reference pursuant to General Instruction E, except to the extent supplemented, amended or superseded by the information set forth herein. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this registration statement.




    Part II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 8.Exhibits.
    EXHIBIT INDEX  
    Exhibit
    No.
      Description
    4.1  
    Amended and Restated Certificate of Incorporation of Absci Corporation (filed as Exhibit 3.1 to the Form 8-K, File No. 001-40646, filed by Absci Corporation on June 16, 2023 and incorporated herein by reference).
    4.2  
    Amended and Restated Bylaws of the Absci Corporation (filed as Exhibit 3.1 to the Form 8-K, File No. 001-40646, filed by Absci Corporation on December 15, 2022 and incorporated herein by reference).
    4.3  
    Investors’ Rights Agreement by and among the Registrant and certain of its stockholders dated October 19, 2020 (filed as Exhibit 4.2 to the Form S-1, File No. 333-257553, filed by Absci Corporation on June 30, 2021 and incorporated herein by reference).
    4.4  
    Specimen Common Stock Certificate (filed as Exhibit 4.1 to the Form S-1, File No. 333-257553, filed by Absci Corporation on July 19, 2021).
    4.5
    Description of Securities (filed as Exhibit 4.3 to the Form 10-K for the year ended December 31, 2021, File No. 001-40646, filed by Absci Corporation on March 22, 2022 and incorporated herein by reference).
    5.1*  
    Opinion of Goodwin Procter LLP.
    23.1*  
    Consent of Independent Registered Public Accounting Firm.
    23.2*  
    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1*  
    Power of Attorney (included on signature page to this registration statement).
    99.1  
    2021 Stock Option and Incentive Plan and forms of award agreements thereunder (filed as Exhibit 10.2 to the Form 10-K for the year ended December 31, 2023, File No. 001-40646, filed by Absci Corporation on March 21, 2023 and incorporated herein by reference).
    99.2
    2021 Employee Stock Purchase Plan (filed as Exhibit 10.3 to the Form S-1, File No. 333-257553, filed by Absci Corporation on July 15, 2021 and incorporated herein by reference).
    107*
    Filing Fee Table.
     
    *Filed herewith.





    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver, Washington, on this 24th day of March, 2026.
     
    ABSCI CORPORATION
    By: /s/ Sean McClain
     Name: Sean McClain
     Title: Founder and CEO

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Sean McClain and Zachariah Jonasson as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their capacities and on the date indicated.



    NAME  TITLE DATE
    /s/ Sean McClain
      
    Founder, CEO and Director
    (Principal Executive Officer)
     March 24, 2026
    Sean McClain
    /s/ Zachariah Jonasson
      
    Chief Financial Officer and Chief Business Officer
    (Principal Financial Officer)
     March 24, 2026
    Zachariah Jonasson, Ph.D.
    /s/ Todd Bedrick
      
    Chief Accounting Officer
    (Principal Accounting Officer)
     March 24, 2026
    Todd Bedrick
    /s/ Frans van Houten
    Chair of the BoardMarch 24, 2026
    Frans van Houten, MSc
    /s/ Karen McGinnis
      Director March 24, 2026
    Karen McGinnis, C.P.A
    /s/ Menelas Pangalos
      Director March 24, 2026
    Prof Sir Menelas Pangalos, Ph.D.
    /s/ Daniel Rabinovitsj
      Director March 24, 2026
    Daniel Rabinovitsj
    /s/ Joseph Sirosh
      Director March 24, 2026
    Joseph Sirosh, Ph.D.
    /s/ Mary Szela
      Director March 24, 2026
    Mary Szela



    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    10/2/2025Overweight
    Analyst
    7/3/2025$7.00Overweight
    Morgan Stanley
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Legal Officer Walker Shelby J. was granted 90,300 shares and covered exercise/tax liability with 9,825 shares, increasing direct ownership by 136% to 139,775 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:56:32 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: CFO / CBO Jonasson Zachariah was granted 135,400 shares and covered exercise/tax liability with 10,848 shares, increasing direct ownership by 33% to 499,783 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:55:34 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SVP, CAO Bedrick Todd was granted 49,600 shares and covered exercise/tax liability with 5,282 shares, increasing direct ownership by 26% to 216,942 units (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    3/16/26 6:53:54 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

    Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported

    3/24/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic

    VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI,  announced the launch of an endometriosis advisory board for its ABS-201 program in clinical development for endometriosis. The Advisory Board consists of endometriosis and clinical development experts with backgrounds from renowned institutions including the Yale University School of Medicine, Duke University School of Medicine, UCSF, and the Mayo Clinic. Endometriosis is a chronic, painful inflammatory disease defined by endometrium-like lesions found outside the uterus affecting an

    3/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci's Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the "Inducement Plan"), and is being made as an inducement material to the new employee's acceptance o

    3/6/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Absci Corporation downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Absci Corporation from Overweight to Equal-Weight and set a new price target of $4.32

    1/8/26 8:35:39 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Analyst initiated coverage on Absci Corporation

    Analyst initiated coverage of Absci Corporation with a rating of Overweight

    10/2/25 8:38:38 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Morgan Stanley resumed coverage on Absci Corporation with a new price target

    Morgan Stanley resumed coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

    7/3/25 7:48:59 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    SEC Filings

    View All

    SEC Form S-8 filed by Absci Corporation

    S-8 - Absci Corp (0001672688) (Filer)

    3/24/26 4:52:15 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by Absci Corporation

    10-K - Absci Corp (0001672688) (Filer)

    3/24/26 4:30:46 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Absci Corp (0001672688) (Filer)

    3/24/26 4:28:17 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas bought $229,000 worth of shares (100,000 units at $2.29), increasing direct ownership by 31% to 421,446 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/16/26 4:17:22 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Pangalos Menelas N bought $205,760 worth of shares (75,095 units at $2.74), increasing direct ownership by 66% to 189,055 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/3/26 4:13:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Van Houten Frans bought $148,800 worth of shares (40,000 units at $3.72), increasing direct ownership by 172% to 63,320 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    12/9/25 4:04:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    View All

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Appoints Biopharma Leader Mary Szela to Board of Directors

    VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal roles in advancing transformative therapies, notably guiding the global launch and expansion of Humira® into multiple indications during her tenure at Abbott Laboratories. "Mary has been a driving force behind the development of one of the most successful therapies in the industry, bringing a rare and invaluable bread

    7/7/25 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

    Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

    1/10/24 7:30:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Financials

    Live finance-specific insights

    View All

    Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

    Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported

    3/24/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

    VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors

    2/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

    Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 Expanding ABS-201 strategy to pursue endometriosis as additional indication; anticipate initiation of Phase 2 clinical trial in the fourth quarter of 2026 Cash, cash equivalents, and marketable securities sufficient to fund operations into the first half of 2028 VANCOUVER, Wash. and NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operat

    11/12/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Absci Corporation

    SC 13G - Absci Corp (0001672688) (Subject)

    11/14/24 4:02:50 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Absci Corporation

    SC 13G/A - Absci Corp (0001672688) (Subject)

    11/12/24 9:50:12 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Absci Corporation (Amendment)

    SC 13D/A - Absci Corp (0001672688) (Subject)

    3/5/24 5:15:30 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care